Eledon Posts Q2 Loss, Holds $88.8M Cash, and Secures FDA Nod for Phase 3 Kidney Trial
ELDN has more than doubled off its 52-week low of $1.35.
Summary
Eledon reported Q2 2026 results with a $31.6M net loss and $88.8M in cash, while announcing FDA alignment to advance tegoprubart into a Phase 3 kidney transplant trial in late 2026.
Key Events · Earnings and Guidance · ELDN
-
FDA End-of-Phase 2 Meeting Successful
A successful End-of-Phase 2 meeting with the FDA has established the regulatory framework for a global Phase 3 kidney transplantation trial of tegoprubart, which is on track to initiate in late 2026 with approximately 600 patients.
-
Q2 Net Loss Widens on Warrant Charge
Net loss for Q2 2026 was $31.6 million, or $0.27 per share, compared to $11.2 million a year earlier. The loss included a $9.6 million non-cash loss from changes in the fair value of warrant liabilities, versus a $12.3 million non-cash gain in Q2 2025.
-
Cash Runway into Q2 2027
Cash, cash equivalents and short-term investments totaled $88.8 million as of June 30, 2026, down from $133.3 million at year-end 2025. Management expects this to fund operations into the second quarter of 2027.
-
Islet Cell Data Shows 100% Insulin Independence
Updated data from the University of Chicago Medicine islet cell transplantation study presented at ADA 2026 showed all 12 patients with type 1 diabetes achieved insulin independence and HbA1c below 6.5%, with no severe hypoglycemic episodes post-transplant.
Analysis · ELDN · Life Sciences
The wider net loss in Q2 stems from a non-cash warrant liability charge, but the pivotal development is the successful End-of-Phase 2 meeting with the FDA, which clears the way for a global Phase 3 kidney transplantation trial expected to begin in late 2026. With $88.8 million in cash, operations are funded into Q2 2027, providing runway through the trial's initiation. Adding clinical validation, the islet cell data showed 100% insulin independence in all 12 patients. Notably, the warrant liability fair-value loss is a non-cash mark-to-market item tied to the share price, not a cash outflow or new dilution.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELDN was trading at $3.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $285.6M. The 52-week trading range was $1.35 to $4.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.